Edgewise Therapeutics, Inc.

EWTX

US28036F1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 16/07/2024 am IST			5-day change	1st Jan Change
22.87 ^USD	+2.01%		+9.32%	+109.05%

09/07	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
09/07	Top Midday Gainers	MT

Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 2500 Value Index

July 01, 2024

Latest news about Edgewise Therapeutics, Inc.

Sector Update: Health Care Stocks Mixed Late Afternoon	10/07	MT
Top Midday Gainers	09/07	MT
JPMorgan Raises Price Target on Edgewise Therapeutics to $30 From $27, Maintains Overweight Rating	09/07	MT
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell Microcap Value Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 3000E Value Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 3000E Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell Microcap Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 3000 Value Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 2500 Value Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell Small Cap Comp Value Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to Russell 3000E Growth Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to Russell 3000 Growth Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 2000 Value Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to Russell 2000 Growth Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to Russell 2500 Growth Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to Russell Small Cap Comp Growth Index	01/07	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to S&P Pharmaceuticals Select Industry Index	24/06	CI
Transcript : Edgewise Therapeutics, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 03:35 PM	16/05
Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating	10/05	MT
Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Edgewise Therapeutics, Inc. Appoints Arlene Morris to Its Board of Directors	07/05	CI
Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial	06/05	MT
Edgewise Therapeutics, Inc Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy	06/05	CI
Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU	23/04	MT
RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk	22/04	MT

Chart Edgewise Therapeutics, Inc.

Duration

Period

More charts

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.87 USD

Average target price

33 USD

Spread / Average Target

+44.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EDGEWISE THERAPEUTICS, INC.	+109.05%	213.6Cr
MODERNA, INC.	+22.15%	4.66TCr
LONZA GROUP AG	+45.94%	4.17TCr
IQVIA HOLDINGS INC.	-2.37%	4.12TCr
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	3.24TCr
CELLTRION, INC.	-6.35%	2.81TCr
ICON PUBLIC LIMITED COMPANY	+20.42%	2.82TCr
UNITED THERAPEUTICS CORPORATION	+48.83%	1.45TCr
MEDPACE HOLDINGS, INC.	+45.00%	1.37TCr
BIO-TECHNE CORPORATION	+0.06%	1.22TCr

Other Biotechnology & Medical Research